Immuneering Corp (IMRX)vsRoyalty Pharma Plc (RPRX)
IMRX
Immuneering Corp
$4.55
+6.31%
HEALTHCARE · Cap: $285.32M
RPRX
Royalty Pharma Plc
$55.02
-1.38%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 536378362% more annual revenue ($2.44B vs $455). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
IMRX
Avoid24
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMRX.
Margin of Safety
-53.4%
Fair Value
$34.53
Current Price
$55.02
$20.49 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRX
The strongest argument for IMRX centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : IMRX
The primary concerns for IMRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
IMRX profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 24/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuneering Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Immuneering Corp (IMRX) is an innovative biotechnology company on the forefront of developing targeted therapeutics for cancer and other serious diseases through its proprietary drug discovery platforms. Utilizing advanced bioinformatics and machine learning techniques, Immuneering is committed to pinpointing and optimizing drug candidates that aim to selectively target critical biological pathways while minimizing toxicity. With a strong portfolio of novel therapies and strategic partnerships, the company is strategically poised to capitalize on the burgeoning fields of personalized medicine and targeted oncology, thereby presenting compelling investment prospects for institutional investors.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?